Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer

Ralph W deVere White, Alexander Tsodikov, Eschelle C. Stapp, Stephanie E. Soares, Hajime Fujii, Robert M. Hackman

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.

Original languageEnglish (US)
Pages (from-to)1036-1043
Number of pages8
JournalNutrition and Cancer
Volume62
Issue number8
DOIs
StatePublished - Nov 2010

Fingerprint

Isoflavones
Genistein
Prostate-Specific Antigen
Prostatic Neoplasms
Equol
Serum
Dietary Supplements
Double-Blind Method
Randomized Controlled Trials
Placebos
Safety
daidzein
Therapeutics

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Oncology
  • Cancer Research

Cite this

Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. / deVere White, Ralph W; Tsodikov, Alexander; Stapp, Eschelle C.; Soares, Stephanie E.; Fujii, Hajime; Hackman, Robert M.

In: Nutrition and Cancer, Vol. 62, No. 8, 11.2010, p. 1036-1043.

Research output: Contribution to journalArticle

deVere White, Ralph W ; Tsodikov, Alexander ; Stapp, Eschelle C. ; Soares, Stephanie E. ; Fujii, Hajime ; Hackman, Robert M. / Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. In: Nutrition and Cancer. 2010 ; Vol. 62, No. 8. pp. 1036-1043.
@article{95cfd90e020d47d380ae667d2fade2f3,
title = "Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer",
abstract = "The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.",
author = "{deVere White}, {Ralph W} and Alexander Tsodikov and Stapp, {Eschelle C.} and Soares, {Stephanie E.} and Hajime Fujii and Hackman, {Robert M.}",
year = "2010",
month = "11",
doi = "10.1080/01635581.2010.492085",
language = "English (US)",
volume = "62",
pages = "1036--1043",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "8",

}

TY - JOUR

T1 - Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer

AU - deVere White, Ralph W

AU - Tsodikov, Alexander

AU - Stapp, Eschelle C.

AU - Soares, Stephanie E.

AU - Fujii, Hajime

AU - Hackman, Robert M.

PY - 2010/11

Y1 - 2010/11

N2 - The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.

AB - The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=78249240074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249240074&partnerID=8YFLogxK

U2 - 10.1080/01635581.2010.492085

DO - 10.1080/01635581.2010.492085

M3 - Article

C2 - 21058191

AN - SCOPUS:78249240074

VL - 62

SP - 1036

EP - 1043

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 8

ER -